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A. Background 
I. Prostate Cancer 
Functional movement is something many healthy people take for granted.  Being able to move 
effectively and confidently is a commodity many men in the US are not able to enjoy.  With 
prostate cancer (PCa), men may experience significant muscle weakness and negative impacts 
on quality of life due to the treatments used to manage advanced disease [1]. The underlying 
mechanisms for the growth of the cancerous prostate tumor are based upon testosterone (T) 
signaling and the conversion of T to dihydrotestosterone (DHT)[2].  Thus, the removal or 
blocking of T signaling is crucial in slowing the growth of these cancerous lesions[2]. However, 
T signaling is important to maintaining a number of physiologic processes, including skeletal 
muscle function[3].  In 2015 the American Cancer Society predicts that 220,800 new cases of 
PCa will develop, and 27,540 men will die from PCa in the United States alone.  One in seven 
men will be diagnosed with prostate cancer during his lifetime[4], and the risk of developing PCa 
increases over one thousand fold from age 40-70[5].  For men that progress to metastatic 
disease the primary treatment is androgen deprivation therapy (ADT), resulting in this 
population suffering from systemic muscle weakness.  Therefore, we aim to investigate the 
underlying mechanisms associated with testosterone depletion on skeletal muscle.   
 
II. Androgen Signaling  
Androgens play a vital role in a large signaling cascade that is initiated within the hypothalamus.  
The hypothalamus is signaled by androgens, in a feedback manner, to produce luteinizing 
hormone-releasing hormone (LHRH).  LHRH exits the hypothalamus and binds to the LHRH-
Receptor (LHRH-R) in the pituitary gland.  This binding starts the production of luteinizing 
hormone (LH), which then travels to the testis to induce the conversion of cholesterol into 
testosterone.  Testosterone is now free to travel to its target tissues, but once it has been 
brought inside a cell of the target tissue, it must be converted to its active form: 
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dihydrotestosterone (DHT).  From here, DHT can bind to the androgen receptor (AR), and the 
AR migrates into the nucleus in order to control genes involved in growth, differentiation, and a 
multitude of other functions[2].   
 
Figure 1: Systemic androgen signaling.  
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Androgens within the body have a feedback system that signal the production of testosterone (T),  and 
eventually T's conversion to dihydrotestosterone (DHT). The signal originates in the hypothalamus which 
in turn produces luteinizing hormone-releasing hormone (LHRH).  LHRH is released, and binds to the 
pituitary gland, which induces production of luteinizing hormone (LH).  The LH migrates to the testis, 
initiating a signal cascade for the conversion of cholesterol to T.  T enters the prostate where it is converted 
to DHT with the help of 5 alpha-reductase.  DHT binds to the Androgen receptor  causing nuclear 
relocation,  that leads to regulation of cell cycle genes.
Xtandi blocks the signal to the nucleus, 
effectively halting growth of cancerous cells
AR
LHRH-R
LH-R
Casodex is an androgen receptor blocker.
Zytiga blocks the synthesis 
of androgens in both the 
adrenal gland and the 
prostate
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ADT drugs act in several ways relative to the androgen signaling process.  The first is to inhibit 
the production of testosterone all together.  The second is to block binding of DHT to the AR 
within the cytoplasm, and the third is to halt the signal from the AR to the nucleus.   
 
III. Muscle Cells 
Muscle cells start out as quiescent satellite cells; small mononuclear muscle precursor cells.  
External stimuli, such as muscle damage, activate these satellite cells - marked by Pax7 
expression - to produce another quiescent satellite cell, and a committed progenitor cell [7].  
The progenitor cells start to express Myf5 along with Pax7 as they move into the cell cycle.  
Once the precursor cells enter into the cell cycle MyoD is up-regulated[6]. The determined state 
of the muscle cell is the myoblast, which continues to proliferate marked by the expression of 
Pax7, MyoD, and Myf5 [7].  The myoblasts exit the cell cycle, and enter into the differentiation 
phase through the down-regulation of cyclin D1, Myf5 and Pax7 [6][7].  The differentiation 
program is marked by the up-regulation of myogenin, along with the continued expression of 
MyoD.  The myoblasts begin to fuse to form multinucleated myotubes.  The differentiation 
transcription factor myogenin, and the proliferation transcription factor Pax7 are mutually 
exclusive in their expression[6], and are key markers of the individual processes. 
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Figure 2: Myoblast activation, proliferation, and differentiation – along with transcriptional 
markers of the processes [7]. 
IV. Testosterone and Muscle 
Testosterone (T), an androgen, plays a vital role in lean muscle mass growth and strength.  A 
study done on the effects of T supplementation in hypogondal men ranging in age from 21-47, 
shows that T supplementation not only raises the amount of lean muscle mass by 9%, but also 
increases strength by 22%[8].   
 
There is evidence that testosterone plays a key role in mediating myoblast proliferation, 
differentiation, and protein synthesis [9] [10].  Introduction of dihydrotestosterone (DHT) – the 
active form of testosterone - to a culture of C2C12 cells significantly induced proliferation of the 
myoblasts[11]. In another study, T introduction during proliferation causes little growth 
changes[9], but when those same cells were transfected with flag-tagged AR, the myoblast 
proliferation was inhibited up to 50%.  Lee et al. posited the explanation that the AR signaling 
pathway suppressed the myoblast proliferation.  The differentiation of those same cells was 
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analyzed, and it was concluded that the AR pathway along with T treatment led to up-regulation 
of myogenin, and accelerated myoblast differentiation [9].   
 
V. Inhibited Testosterone Signaling and its Physiological Effects 
ADT drugs are effective at lowering the concentrations of androgens, or inhibiting the AR 
signaling cascade[12].  The lowering of effective testosterone within a system leads to 
physiological effects.  These physiological effects lead to functional declines, such as 
weakness, loss of muscle mass, and fat gain[4].  Alibhai et al quantified the functional declines 
of patients on ADT[1].  The authors measured three functional movements: a six-minute walk 
test, a grip strength test, and a timed-up-and-go test, in order to simulate effective movement, 
upper extremity strength, and core strength respectively.  The timed-up-and-go test was the 
amount of time it took a person to stand up from a chair and begin to walk, the grip strength 
measured the force imparted by the man’s grip, and the six-minute walk test measured the 
distance traveled in six minutes. Patients on ADT performed significantly worse on both the grip 
strength and timed-up-and-go tests as compared to prostate cancer controls, and healthy 
controls, and exhibited a trend of worsened performance in the six-minute walk test.  
 
In a review by Storer, et al the authors looked at various studies to assess the strength and 
functional performance of prostate cancer patients on ADT[13]. Grip strength in ADT patients 
was 5% lower than healthy controls, ADT patients were an average of 0.24 seconds slower in a 
walking test and ADT patients were significantly slower in completing 5 chair stands.  The 
decrease in strength in patients undergoing ADT leads to a lower quality of life.  Combined, 
these studies demonstrate a clear systemic impact of ADT on muscle function.   
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VI. Pre-Clinical Systems to Study the Effect of Low Testosterone on Skeletal Muscle 
We aim to investigate the impact of low testosterone status in comparison with clinically relevant 
pharmacologic agents on myoblast proliferation and differentiation, and their associated 
mechanisms.  Understanding the underlying mechanisms will provide insight into future 
strategies for limiting these adverse effects, such as with exercise or targeted therapies. There 
are a variety of well-established pre-clinical systems available to conduct preliminary studies.  
The C2C12 line is a model of mouse skeletal myoblasts that were originally harvested from the 
thigh muscle of a two-month-old female mouse.  There is a well-established protocol for in vitro 
proliferation and differentiation using this model that makes the C2C12 cell culture system an 
invaluable tool in order to study the molecular effects of low testosterone status[14].  Figure 2 
shows the three main ways that molecular mechanisms of action are studied in animals.  Cell 
lines were the best option for this analysis, because they remain relatively constant over short 
periods of time, and they are easy to culture, collect, and analyze.  The reproducibility is a very 
desirable trait of the C2C12 cell line, along with the wealth of literature characterizing this cell 
line.   
Figure 3: Mediums for studying molecular mechanisms of action. 
 
Types of Cell Cultures 
Type Description Primary Uses Disadvantages 
Primary 
Cell 
Cultures 
Cells that have been 
directly harvested 
and maintained 
temporarily in a cell 
culture system 
Studying specific organs 
at the cellular level in 
cells that have not 
undergone 
transformation 
Isolates cells from their natural 
"habitat", does not take into account 
effects from rest of body, difficult to 
isolate single cell types 
In Vivo Living Organism Provides a holistic view 
of the causes and 
effects of the subject 
matter 
Difficult to isolate the specific functions 
and mechanisms within individual cell 
types 
Cell Lines Population of 
immortalized cells  
Very reproducible 
system of a single cell 
type. Investigate 
individual cell types in 
isolation, and their 
cellular processes 
Immortalized cells can change over 
time in culture and no longer represent 
the primary tissue; Can only study the 
mechanisms of a very specific cell line 
such as muscle or fatty tissue.  
Removed from natural "habitat" 
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VII. Proliferation and Differentiation Model of C2C12 Muscle Cells 
The proliferation and differentiation model of the C2C12 cell system is well defined, and can be 
monitored via several mechanisms.  Proliferating C2C12 myoblasts are supplemented with 10-
20% fetal bovine serum (FBS), and allowed to grow until ~80-90% confluent.  Once the desired 
confluencey is reached, the myoblasts are traditionally switched to a 1-3% horse serum (HS) 
media.  The reduction in nutritional content in the media forces the myoblasts out of the cell 
cycle, and induces differentiation.  During differentiation the myoblasts fuse to one another to 
form multinucleated myotubes. 
Figure 4: Picture of myogenesis: proliferation of myoblasts through differentiation into 
myotubes[14]. 
 
VIII. Tools to Evaluate Proliferation and Differentiation 
Analysis of proliferative progress is most commonly done with an absorbance assay.  The cells 
are treated with certain reagents that interact with a protein, ATP, etc. and the more abundant 
the target molecule, the greater the theoretical number of cells, and thus a larger absorbance 
value. 
 
Fully differentiated myotubes can be analyzed through counting of multinucleated myotubes.  
This gives a relative number of myoblasts that have fused, and helps quantify the extent of 
differentiation within a culture. 
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Gene expression patterns during the proliferation and differentiation phases are exclusively 
unique, and well defined.   Cyclin D1 and p21 both mediate cell cycle phase transitions during 
proliferation, while myogenin and GRIP-1 are key markers of differentiation.  The myosin heavy 
chain isoforms are characteristic of fully differentiated myotubes.  By measuring the relative 
expressions of these genes at various time points, the stages of growth and fusion of myoblasts 
can be monitored[14]. 
 
IX. Proteomics 
Proteomic analysis of the cells at various time points furthers the depth of knowledge of cell 
status.  The proteome of the C2C12 system has recently been defined[15].  Proteomics is 
utilized to identify key proteins that point to the status of the culture as a whole; whether the 
cells are proliferating and differentiating unhindered, or whether the cell cultures are undergoing 
some sort of stress from treatment.  The inherent depth of proteomic analysis allows for wide 
spectrum examination of key protein changes or analysis of consistent protein expression 
during the time course.    
 
B. Hypothesis 
We hypothesize that low testosterone status will alter the myoblast proliferation and 
differentiation processes necessary for sustained skeletal muscle function. 
 
C. Experimental Design and Aims 
I. Specific Aims 
Specific aim 1: We hypothesize that there will be key pathway changes within the C2C12 
myoblast proliferation and differentiation program. (20% fetal bovine serum (FBS) during 
proliferation, 2% FBS during differentiation.) 
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Sub-Aim 1: To determine if substituting 2% FBS for 2% horse serum (HS) during 
differentiation is a sufficient mean of inducing differentiation. 
Sub-Aim 2:  To examine the proteomic profile, and identify the key pathway changes of 
the differentiation process. 
 
Specific aim 2:  We hypothesize that low testosterone status will effect the myoblasts on a 
molecular level. 
Sub-Aim 1: To determine the pathway changes associated with low testosterone status 
on the C2C12 culture. 
Sub-Aim 2: To establish the molecular implications of low testosterone status on the 
C2C12 culture. 
 
II. Research Strategies and Methods 
Experiment 1: The pilot study of the differences between 2% HS and 2% FBS to induce 
differentiation was run under general cell culture conditions with 2% HS (Atlanta Biologicals, 
S12195, Lawrenceville, GA) for one culture of cells to induce differentiation, and 2% FBS to 
induce differentiation in another.  Cell aliquots were collected from time points: -24h through 
96h, and analyzed using qRT-PCR along with bright field images at 4x, 10x, 20x, and 40x 
magnification. 
 
The determination of the key pathways involved in the proliferation and differentiation of muscle 
cells was accomplished via analysis of the proteomic profile, qRT-PCR array of total RNA, and 
image collection.  Cell pellets from -48h through 96h were collected.  The proteome of the -24, 
0h, 48h and 96h time points was analyzed, and the -24h, 0h, and 96h time points were analyzed 
with a qRT-PCR Array. 
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Figure 5: Parameters measured and the time period - for the standard proliferation and 
differentiation protocol. 
 
Experiment 2:  The effects of testosterone depletion in culture were examined proteomically and 
transcriptionally.  These results were augmented with cell viability testing via the cell 
proliferation assay.  Four treatment groups were tested: control group (C), removal of 
testosterone during proliferation (P), removal during differentiation (D), and removal throughout 
the entire time course (PD).  Charcoal stripped FBS was used in place of regular FBS during the 
periods of testosterone removal.  Cells proliferated on 10 cm tissue plates from -48h to 0h.  
Differentiation was induced at the 0h time point by switching the cultures to 2% media.  The 
cells were allowed to differentiate through 96h, with media being refreshed every 24 hours.  Cell 
pellets were collected every 24 hours for the entirety of the time course. 
Figure 6: Parameters measured and the time period - for the testosterone depletion study of 
proliferation and differentiation. 
 
  Parameters Measured 
Time Period -48h -24h 0h 24h 48h 72h 96h 
Proliferation Assay X X X X X X X 
Gene Array  X X    X 
Proteome  X X  X  X 
Images X X X X X X X 
Parameters Measured 
Time Period -48h -24h 0h 24h 48h 72h 96h 
Proliferation Assay X X X X X X X 
Gene Array  X X    X 
Proteome  X X    X 
Images X X X X X X X 
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Cell Culture Conditions and Reagents:  C2C12 mouse skeletal myoblasts (American Type 
Culture Collection, CRL-1772, Manassas, VA) were plated at 1.5x105 cells per plate at -72h, 
and maintained in 10 mL of a 20% FBS (Omega Scientific, FB-12, Tarzana, CA) in DMEM 
(American Type Culture Collection, 30-2002, Manassas, VA) containing 0.01% 100x 
antibiotic/antimycotic, (Gibco, 15240, Grand Island, NY) and termed growth media (GM).  The 
cultures were kept in a controlled environment at 370C, with 5% CO2 supplementation.  The 
cells proliferated until 90-100% confluent, and were then switched to a differentiation media 
(DM) of 2% FBS in DMEM from the 0h time point through the terminal 96h time point.  Media 
was refreshed every 24 hours during the entire time course.  Images were taken on a bright-
field microscope at 4x, 10x, 20x, and 40x magnification for each time point and condition. Cell 
pellets were subsequently collected, snap frozen in liquid nitrogen, and stored in a -800C freezer 
for downstream analysis. 
 
Proliferation Assay:  Cell viability was quantitatively determined using the In Vitro Toxicology 
Assay Kit, Sulforhodamine B Based (Sigma, TOX6-1KT, St. Louis, MO).  96-well plates were 
plated with 1750 cells per well - 2 columns (excluding the edges) per condition for the 
testosterone depletion study - for a total of 8 columns.  The cytotoxicity of the treatments was 
tested per Sigma’s manufacturer instructions. 
 
RNA Extraction:  Extraction of total RNA was accomplished using the RNeasy Mini Kit (Qiagen, 
74106, Maryland), and a QIAshredder (Qiagen, 79054, Maryland) to lyse the cell pellets.  All 
manufacturers’ instructions were followed.   
 
Single Gene qRT-PCR:  Single gene PCR was run for all time points for the HS vs. FBS study, 
on the genes listed in Figure 7.  cDNA was synthesized via the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, 4368814, Foster City, CA) according to the 
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manufacturer’s instructions.  Subsequent PCR was run utilizing SYBR Green PCR Master Mix 
(Applied Biosystems, 4309155, Foster City, CA) on MicroAmp Fast Optical 96-wll Reaction 
Plates (Applied Biosystems, 4346906, China).  qRT-PCR was carried out at the Nucleic Acid 
Shared Resource at The Ohio State University. 
Figure 7: Genes measured with single gene PCR and their function [14]. 
 
qRT-PCR Array: The Mouse Skeletal Muscle: Myogenesis and Myopathy RT2 PCR Array 
(QIagen, 330231, Maryland) was run for the -24h, 0h, and 96h time points of the testosterone 
depletion study.  cDNA was synthesized per manufacturer’s instructions using the RT2 First 
Strand Kit (Qiagen, 330401, Maryland).  The 384-well plates were prepared according to the 
manufacturer’s directions using RT2 SYBR Green ROX qPCR Mastermix, (Qiagen, 330521, 
Maryland) and 400 ng of total RNA from each sample.  Samples were run at the OSU Nucleic 
Acid Shared Resource.   
 
Proteomic Profiling: 
Tissue Lysis and Protein Digestion 
Gene 
Name 
Gene Bank 
Accession # 
Sense Primer (5'-3') Antisense Primer (5'-3') Gene Function 
Cyclophilin NM0089071 CCCACCGTGTTCTTCGACAT  TTCTCTCCAGTGCTCAGAGC Accelerates folding of proteins 
Myogenin NM0311891 AGCTGTATGAGACATCCCCC  TTCTTGAGCCTGCGCTTCTC  Myogenin is required to fuse precursor 
cells to muscle fibers during 
differentiation 
Cyclin D1 NM0076311 CGTGGCCTCTAAGATGAAGG  TGTTCTCATCCGCCTCTGGC  Regulates cell cycle - required for the 
G1/S transition 
p21 U24173 CGGTGGAACTTTGACTTCGT  CAGGGCAGAGGAAGTACTGG  Cyclin dependent kinase inhibitor - 
mediates G1 and S phases 
AR NM013476 TACCAGCTCACCAAGCTCCT  GATGGGCTTGACTTTCCCAG  Androgen receptor – Critical in many 
development cunctions 
GRIP-1 NM008678 ACAGAACCAGCCAAACCAAC  TGGTTGAGGATTTCCCTCTG  Steroid receptor - Interacts with MEF-
2C mediated transcription and 
formation myotubes - believed to play 
crucial role in muscle cell 
differentiation  
MyHC-IIb BC052786 GAGCAGCTGGCGCTGAAGGG  GATTTCTCCTGTCACCTCTC  Predominant Motor protein in skeletal 
muscle  
MyHC IIx/d XM354615 TCAATGAGCTGACTGCGCAG  CAAGCTGCCTCTTCAGCTCC  Terminally differentiated muscle cell 
markers (ALL MyHC) 
MyHC-I NM080728 AAGATCGTGTCCCGAGAGGG  TTGTACAGCACAGCCGGCTC  Marker for fully differentiated 
myotubes 
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Cell pellets were digested. Briefly, 100,000 cells were homogenized in a lysis buffer consisting 
of 9:1 (v/v) ratio of ammonium bicarbonate (50mM) and acetonitrile containing 0.1% (w/v) 
ProteaseMAX surfactant (Promega, Madison, WI, USA) with the aid of rigorous vortexing. This 
protein homogenate disulfide bonds were reduced with DTT (5mM) at 56°C, 750RPM for 20 
minutes. Reduced disulfide bonds were alkylated with iodoacetamide (10mM) at 25°C in the 
dark for 30 minutes. Tryptic peptides were produced through digestion with sequence grade 
trypsin (Promega, Madison, WI, USA) at a ratio of 1:40 (w/w) at 37°C for 9 h under constant 
agitation (1,000 RPM). ProteaseMAX surfactant was denatured by the addition of 5% formic 
acid (v/v) then heated at 45°C under constant agitation (800 RPM) for 20 minutes. Peptide 
mixtures were cleared by centrifugation (21,000xG), dried to dryness using a vacuum 
centrifugation and resuspended in 0.1% formic acid. Final peptide concentration was 
determined by 280nm absorbance using a NanoDrop ND-1000 spectrometer (NanoDrop, 
Wilmington, DE, USA)[16].   
 
Instrument Conditions 
 
Based on 280nm absorbance, 2μg of peptide mixture was separated by reverse phase liquid 
chromatography (RP-LC). Peptides were desalted at 10uL/min with a trap column, and 
subsequently separated across an analytical column (0.075 x 150 mm, PepMap C18, 3 μm 100 
Å, Thermo Scientific, Waltham, MA). Peptides were introduced into a Velos Pro-ETD dual-
pressure linear ion trap mass spectrometer (Thermo Scientific, Waltham, MA) with a EASY-
Spray Ion source (Thermo Scientific, Waltham, MA). Two mobile phases were used MPA (0.1% 
formic acid in HPLC water) and MPB (0.1% formic acid in acetonitrile). Reverse phase analytical 
separation was completed at 600 nL/min using a 175-minute gradient from 5% to 45% MPB 
followed by gradient adjustment to 90% MPB over 5 minutes with a 5 minute hold at 90% MPB. 
Finally the gradient was adjusted to 95% MPB to wash the column and was equilibrated to 5% 
MPB prior to the next analytical separation. Spray voltage and capillary temperature was set to 
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1.8 kV and 275°C. A single top-speed data cycle was completed in data-dependent acquisition 
(DDA) mode consisting of a single full MS scan (AGC target: 30,000 ions; maximum injection 
time of 150 ms; 1 microscan) followed by 10 MS/MS scans in the linear ion trap (AGC target: 
10,000 ions; maximum injection time of 150 ms; 1 microscan). Precursor ions of 1+ charge were 
rejected. Ion range was confined to 400-1700 m/z with signal abundance above 80,000 TIC 
were selected for CID fragmentation (35% NCE, q=0.25, 2 m/z isolation width and 10 ms 
activation time). DDA dynamic exclusion was enabled with a repeat count of one (45s – 1 Da, 
45s + 2 Da). 
 
Statistical Methods:  In Sigma Plot, expression values for the qRT-PCR array were log 
transformed (LN) and subsequently tested for normality using the Shapiro-Wilk test.  Next the 
expression values underwent the Brown-Forsythe Equal Variance Test.  Pairwise comparisons 
were made using a 2-way ANOVA with the Holm-Sidak method, with a significance level set to 
p=0.05[17].   
 
Proteomic data was uploaded to Ingenuity Pathway Analysis (IPA) (Ingenuity Systems), where 
the data was arranged into predicted pathways based on the fold changes and p-values, as 
compared to known literature pathways.   
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D. Results 
Investigation into Legitimacy of Fetal Bovine Serum Instead of Horse Serum to induce 
Differentiation – The traditional method of inducing differentiation in C2C12 myoblasts was to 
switch from fetal bovine serum (FBS) to adult horse serum (HS) at a low concentration. The 
reason was the HS had fewer growth factors because it came from an adult, and because HS 
was provided in a 10-fold lower concentration.  The change to a serum with lower amounts of 
growth factors slowed down the proliferation of the myoblasts, and pushed them towards 
leaving the cell cycle, and differentiating into multinucleated myotubes.  The C2C12 myoblast 
cell culture system was tested using both 2% HS to induce differentiation, and 2% FBS.  The 
switch to 2% FBS did not drastically alter the phenotypic differentiation program (Fig. 1). 
 
  
 
 
 
 
 
 
Figure 7: C2C12 culture using 2% FBS vs. 2% HS during differentiation, 40x magnification. 
To verify the phenotypic patterns, RNA expression analyses were run on key genes for both the 
proliferation and differentiation programs.  These genes were: Myogenin, Grip-1, Cyclin D1, and 
MyHC IIx/d.  The relative expressions for both the 2% HS and the 2% FBS were very similar for 
all time points (Fig. 2). 
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Figure 8: Relative expression (2-(dCT)) of 4 key genes throughout the time course relative to the 
0h time point. Red represents HS, and blue represents FBS. 
 
 
The differentiating myoblasts with the 2% FBS followed the trends set by the myoblasts with the 
2% HS.  Key genes were up- or down-regulated during the same time points.  After this initial 
analysis, it was concluded that the 2% FBS suitably pushed the C2C12 myoblasts into 
differentiation, and provided an environment conducive to myoblast fusion and myotube 
formation. 
 
Proteomic Analysis of the C2C12 Differentiation Program – Our proteomic analysis of the 
C2C12 culture system provided an in-depth look into the pathway effects of differentiation.  
Three observations were analyzed via the Ingenuity Pathway Analysis software: -24h to 0h, 48h 
to 0h, and 96h to 0h.  These time points are relative to the fully proliferated state of the 
myoblasts.  The -24h to 0h analysis showed the changes during proliferation, the 48h to 0h 
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showed the early differentiation changes, and the 96h to 0h showed the late differentiation 
changes.   
 
Starting with the -24h to 0h observation, it was noted that the top canonical pathways for the -
24h state relative to the 0h state were epithelial adherens junction signaling, calcium signaling, 
actin cytoskeleton signaling, and tight junction signaling.  
Epithelial Junction Signaling Proteins Present (9/97) 
Symbol Gene Name Log ratio p-value 
MYH4 myosin heavy chain 4, skeletal muscle -5.048 5.44e-04 
MYH1 myosin heavy chain 1, skeletal muscle, adult -4.300 1.64e-02 
CTNNB1 catenin beta 1 -1.626 9.35e-02 
IQGAP1 IQ motif containing GTPase activating protein 1 -0.425 9.66e-02 
MYL1 Myosin light chain 1, skeletal, fast 0 0 
MYL3 myosin light chain 3, skeletal, slow 0 0 
MYL4 myosin light chain 4, atrial, embryonic 0 0 
YES1 YES proto-oncogene 1 0 0 
Actn3 actinin alpha 3 0.764 9.04e-2 
 
Actin Cytoskeleton Signaling Proteins Present (9/128) 
Symbol Gene Name Log Ratio p-value 
ACTN3 actinin alpha 3 0.764 9.04e-02 
GSN gelsolin -0.868 5.00e-02 
IQGAP1 IQ motif containing GTPase activating protein 1 -0.425 9.66e-02 
MYH1 myosin, heavy chain 1, skeletal muscle, adult -4.300 1.64e-02 
MYH4 myosin, heavy chain 4, skeletal muscle -5.048 5.44e-04 
MYL1 myosin, light chain 1, alkali; skeletal, fast 0.000 0 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 0.000 0 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 0.000 0 
MYLPF myosin light chain, phosphorylatable, fast skeletal muscle 0.000 0 
 
Calcium Signaling Proteins Present (9/114) 
Symbol Gene Name Log Ratio p-value 
MYH1 myosin, heavy chain 1, skeletal muscle, adult -4.300 1.64e-02 
MYH4 myosin, heavy chain 4, skeletal muscle -5.048 5.44e-04 
MYL1 myosin, light chain 1, alkali; skeletal, fast 0.000 0 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 0.000 0 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 0.000 0 
TNNC2 troponin C type 2 (fast) 0.000 0 
TNNI1 troponin I type 1 (skeletal, slow) 0.000 0 
TNNT2 troponin T type 2 (cardiac) 0.000 0 
TNNT3 troponin T type 3 (skeletal, fast) 0.000 0 
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Tight Junction Signaling Proteins Present (8/111) 
Symbol Entrez Gene Name Log Ratio p-value 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa -1.626 9.35e-02 
MYH1 myosin, heavy chain 1, skeletal muscle, adult -4.300 1.64e-02 
MYH4 myosin, heavy chain 4, skeletal muscle -5.048 5.44e-04 
MYL1 myosin, light chain 1, alkali; skeletal, fast 0.000 0 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 0.000 0 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 0.000 0 
NAPA N-ethylmaleimide-sensitive factor attachment protein, alpha 0.000 0 
VAPA 
VAMP (vesicle-associated membrane protein)-associated 
protein A, 33kDa 
-2.612 3.96e-02 
 
The second observation was the 0h time point relative to the 48h time point.  The top pathways 
were as follows: 
Cellular Effects of Sildenafil Proteins Present (6/62) 
Symbol Entrez Gene Name Log Ratio p-value 
MYH1 myosin, heavy chain 1, skeletal muscle, adult -4.300 1.64E-02 
MYH4 myosin, heavy chain 4, skeletal muscle -5.048 5.44E-04 
MYL1 myosin, light chain 1, alkali; skeletal, fast 0.000 0.00E00 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 0.000 0.00E00 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 0.000 0.00E00 
MYLPF myosin light chain, phosphorylatable, fast skeletal muscle 0.000 0.00E00 
Calcium Signaling Proteins Present (19/114) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.366 3.13E-02 
ACTA2 actin, alpha 2, smooth muscle, aorta 0.373 3.99E-02 
ACTC1 actin, alpha, cardiac muscle 1 0.327 5.61E-02 
ATP2A1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 2.587 4.85E-04 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 2.543 3.29E-04 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 3.224 9.77E-04 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 5.311 1.16E-07 
MYH4 myosin, heavy chain 4, skeletal muscle 2.457 2.62E-03 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 3.884 3.97E-03 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 2.720 2.93E-03 
MYL1 myosin, light chain 1, alkali; skeletal, fast 6.565 2.07E-07 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 4.117 3.54E-02 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 6.076 1.84E-05 
TNNC2 troponin C type 2 (fast) 0.000 0.00E00 
TNNI1 troponin I type 1 (skeletal, slow) 4.505 8.32E-03 
TNNT2 troponin T type 2 (cardiac) 4.950 1.25E-03 
TNNT3 troponin T type 3 (skeletal, fast) 4.326 1.76E-02 
Tpm1 tropomyosin 1, alpha 1.032 3.67E-04 
Tpm2 tropomyosin 2, beta 1.521 7.92E-06 
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Cellular Effects of Sildenafil Proteins Present (13/62) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.366 3.13E-02 
ACTA2 actin, alpha 2, smooth muscle, aorta 0.373 3.99E-02 
ACTC1 actin, alpha, cardiac muscle 1 0.327 5.61E-02 
GNAS GNAS complex locus 1.797 6.10E-02 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 3.224 9.77E-04 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 5.311 1.16E-07 
MYH4 myosin, heavy chain 4, skeletal muscle 2.457 2.62E-03 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 3.884 3.97E-03 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 2.720 2.93E-03 
MYL1 myosin, light chain 1, alkali; skeletal, fast 6.565 2.07E-07 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 4.117 3.54E-02 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 6.076 1.84E-05 
MYLPF myosin light chain, phosphorylatable, fast skeletal muscle 4.855 1.18E-02 
Epithelial Adherens Junction Signaling Proteins Changes (15/97) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.366 3.13E-02 
ACTA2 actin, alpha 2, smooth muscle, aorta 0.373 3.99E-02 
ACTC1 actin, alpha, cardiac muscle 1 0.327 5.61E-02 
Actn3 actinin alpha 3 1.394 6.37E-03 
CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa 0.786 8.16E-02 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 3.224 9.77E-04 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 5.311 1.16E-07 
MYH4 myosin, heavy chain 4, skeletal muscle 2.457 2.62E-03 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 3.884 3.97E-03 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 2.720 2.93E-03 
MYL1 myosin, light chain 1, alkali; skeletal, fast 6.565 2.07E-07 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 4.117 3.54E-02 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 6.076 1.84E-05 
VCL vinculin 0.454 9.69E-03 
YES1 YES proto-oncogene 1, Src family tyrosine kinase 0.000 0.00E00 
20 
 
ILK Signaling Protein Changes (15/115) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.366 3.13E-02 
ACTA2 actin, alpha 2, smooth muscle, aorta 0.373 3.99E-02 
ACTC1 actin, alpha, cardiac muscle 1 0.327 5.61E-02 
Actn3 actinin alpha 3 1.394 6.37E-03 
FLNB filamin B, beta -0.609 8.50E-03 
FLNC filamin C, gamma 0.857 1.98E-06 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 3.224 9.77E-04 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 5.311 1.16E-07 
MYH4 myosin, heavy chain 4, skeletal muscle 2.457 2.62E-03 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 3.884 3.97E-03 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 2.720 2.93E-03 
MYL1 myosin, light chain 1, alkali; skeletal, fast 6.565 2.07E-07 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 4.117 3.54E-02 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 6.076 1.84E-05 
VIM vimentin -0.194 6.38E-02 
 
Actin Cytoskeleton Signaling Protein Changes (15/128) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.366 3.13E-02 
ACTA2 actin, alpha 2, smooth muscle, aorta 0.373 3.99E-02 
ACTC1 actin, alpha, cardiac muscle 1 0.327 5.61E-02 
Actn3 actinin alpha 3 1.394 6.37E-03 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 3.224 9.77E-04 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 5.311 1.16E-07 
MYH4 myosin, heavy chain 4, skeletal muscle 2.457 2.62E-03 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 3.884 3.97E-03 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 2.720 2.93E-03 
MYL1 myosin, light chain 1, alkali; skeletal, fast 6.565 2.07E-07 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 4.117 3.54E-02 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 6.076 1.84E-05 
MYLPF myosin light chain, phosphorylatable, fast skeletal muscle 4.855 1.18E-02 
TTN titin 0.651 6.34E-03 
VCL vinculin 0.454 9.69E-03 
 
 
The third observation was from the 0h time point to the 96h time point.  The top canonical 
pathways were as follows: 
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Calcium Signaling Pathway Protein Changes (20/114) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.751 1.50E-08 
ACTA2 actin, alpha 2, smooth muscle, aorta 0.810 4.90E-09 
ACTC1 actin, alpha, cardiac muscle 1 0.684 1.53E-07 
ATP2A1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 4.481 2.45E-15 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 3.658 1.17E-08 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 5.718 1.94E-14 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 6.875 1.11E-24 
MYH4 myosin, heavy chain 4, skeletal muscle 4.760 4.63E-13 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 6.559 1.22E-15 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 5.108 4.77E-18 
MYL1 myosin, light chain 1, alkali; skeletal, fast 8.120 1.50E-24 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 5.918 7.27E-07 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 7.336 1.59E-15 
TNNC2 troponin C type 2 (fast) 4.664 4.25E-03 
TNNI1 troponin I type 1 (skeletal, slow) 5.849 1.62E-06 
TNNT2 troponin T type 2 (cardiac) 5.920 8.01E-07 
TNNT3 troponin T type 3 (skeletal, fast) 5.175 3.12E-04 
Tpm1 tropomyosin 1, alpha 1.456 4.06E-08 
Tpm2 tropomyosin 2, beta 2.074 8.43E-12 
Tpm4 tropomyosin 4 -0.973 7.92E-03 
 
ILK Signaling Protein Changes (18/115) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.751 1.50E-08 
ACTA2 actin, alpha 2, smooth muscle, aorta 0.810 4.90E-09 
ACTC1 actin, alpha, cardiac muscle 1 0.684 1.53E-07 
ACTN2 actinin, alpha 2 0.639 7.35E-02 
Actn3 actinin alpha 3 2.172 2.54E-06 
FLNA filamin A, alpha -0.554 7.31E-02 
FLNB filamin B, beta -1.217 2.71E-07 
FLNC filamin C, gamma 1.491 1.81E-15 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 5.718 1.94E-14 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 6.875 1.11E-24 
MYH4 myosin, heavy chain 4, skeletal muscle 4.760 4.63E-13 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 6.559 1.22E-15 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 5.108 4.77E-18 
MYL1 myosin, light chain 1, alkali; skeletal, fast 8.120 1.50E-24 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 5.918 7.27E-07 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 7.336 1.59E-15 
NACA nascent polypeptide-associated complex alpha subunit 1.268 1.88E-05 
VIM vimentin -0.362 1.46E-02 
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Epithelial Adherens Junction Signaling Protein Changes (16/197) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.751 1.50E-08 
ACTA2 actin, alpha 2, smooth muscle, aorta 0.810 4.90E-09 
ACTC1 actin, alpha, cardiac muscle 1 0.684 1.53E-07 
ACTN2 actinin, alpha 2 0.639 7.35E-02 
Actn3 actinin alpha 3 2.172 2.54E-06 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 5.718 1.94E-14 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 6.875 1.11E-24 
MYH4 myosin, heavy chain 4, skeletal muscle 4.760 4.63E-13 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 6.559 1.22E-15 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 5.108 4.77E-18 
MYL1 myosin, light chain 1, alkali; skeletal, fast 8.120 1.50E-24 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 5.918 7.27E-07 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 7.336 1.59E-15 
TUBB6 tubulin, beta 6 class V 0.301 9.91E-02 
VCL vinculin 0.563 1.46E-03 
YES1 YES proto-oncogene 1, Src family tyrosine kinase 4.107 3.29E-02 
 
Actin Cytoskeleton Signaling Protein Changesz (18/128) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.751 1.50E-08 
ACTA2 actin, alpha 2, smooth muscle, aorta 0.810 4.90E-09 
ACTC1 actin, alpha, cardiac muscle 1 0.684 1.53E-07 
ACTN2 actinin, alpha 2 0.639 7.35E-02 
Actn3 actinin alpha 3 2.172 2.54E-06 
EZR ezrin -0.541 9.07E-02 
FLNA filamin A, alpha -0.554 7.31E-02 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 5.718 1.94E-14 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 6.875 1.11E-24 
MYH4 myosin, heavy chain 4, skeletal muscle 4.760 4.63E-13 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 6.559 1.22E-15 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 5.108 4.77E-18 
MYL1 myosin, light chain 1, alkali; skeletal, fast 8.120 1.50E-24 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 5.918 7.27E-07 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 7.336 1.59E-15 
MYLPF myosin light chain, phosphorylatable, fast skeletal muscle 7.402 5.21E-11 
TTN titin 1.066 1.66E-03 
VCL vinculin 0.563 1.46E-03 
 
 
 
Mitochondrial Dysfunction Proteins Present (17/123) 
Symbol Entrez Gene Name Log Ratio p-value 
ACTA1 actin, alpha 1, skeletal muscle 0.751 1.50E-08 
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ACTA2 actin, alpha 2, smooth muscle, aorta 0.810 4.90E-09 
ACTC1 actin, alpha, cardiac muscle 1 0.684 1.53E-07 
ACTN2 actinin, alpha 2 0.639 7.35E-02 
Actn3 actinin alpha 3 2.172 2.54E-06 
EZR ezrin -0.541 9.07E-02 
FLNA filamin A, alpha -0.554 7.31E-02 
MYH1 myosin, heavy chain 1, skeletal muscle, adult 5.718 1.94E-14 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 6.875 1.11E-24 
MYH4 myosin, heavy chain 4, skeletal muscle 4.760 4.63E-13 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 6.559 1.22E-15 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 5.108 4.77E-18 
MYL1 myosin, light chain 1, alkali; skeletal, fast 8.120 1.50E-24 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 5.918 7.27E-07 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 7.336 1.59E-15 
MYLPF myosin light chain, phosphorylatable, fast skeletal muscle 7.402 5.21E-11 
TTN titin 1.066 1.66E-03 
VCL vinculin 0.563 1.46E-03 
 
The predicted top upstream regulators were analyzed along with the top canonical pathways.  
The upstream regulators were both identified, and a prediction made on the state of activation.  
The top upstream regulators for all time periods as identified by IPA were as follows: 
 
INSR:  
 
 
 
 -24h to 0h                                          48h to 0h                                                   96h to 0h 
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TP53: 
  
 
-24h to 0h                                             48h to 0h                                                        96h to 0h 
 
 
 
SRF: 
 
 
-24h to 0h                                           48h to 0h                                                      96h to 0h 
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IGF1R: 
     
 
NO DATA 
 
 
  
 
-24h to 0h                                      48h to 0h                                                      96h to 0h 
 
Figure 9: Top upstream regulators of the differentiation process – pairwise comparison between 
the time points. 
 
Figure 9 shows the top upstream regulators predicted by IPA.  The top regulators of the 
differentiation process were INSR, TP53, SRF and IGF1R.  These molecules regulate the 
process in various ways, and are critical the differentiation of myoblasts. 
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Transcriptional analysis of testosterone depletion during the proliferation and differentiation 
programs - The C2C12 mouse myoblast cells were treated with charcoal stripped FBS (CS-
FBS) during the proliferation phase (P), the differentiation phase (D), and throughout the entire 
time course (PD), as seen in Figure 10. 
     
Figure 10: Pictures of the different treatment groups undergoing the differentiation process. 
 
The cells were visually less confluent at 0h after being treated with CS-FBS.  When undergoing 
differentiation, having full media (not charcoal stripped) led to longer myotube formation.  A 
myogenesis PCR array was run to confirm the phenotypic changes.  The -24h, 0h, and 96h time 
points were selected for analysis because they showed the greatest phenotypic changes for the 
control group.  Below are the functional gene groupings along with their relative expressions: 
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Skeletal Muscle Contractility: 
Fast-Twitch Fibers: 
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Skeletal Muscle Autocrine Signaling: 
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Adipoq, Lep, and Mstn not shown because they were below the detectable limit for all time 
points. 
 
Proteomic analysis of the testosterone depleted proliferation and differentiation programs- A 
four-way Venn diagram was constructed based on the major proteins present at the 0h and 96h 
time points for each treatment group.  A pairwise comparison was made between the 96h period 
of the treatment group and its 0h time point.  The pairwise comparisons were then gathered, 
and a four-way Venn diagram constructed that showed the common proteins between the 
pairwise comparisons.  The numbers of common proteins present were as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: 4-way Venn Diagram for the unique, differential expression of proteins with the 3 
treatment groups, and the control group.  The comparisons are 96h to 0h for each respective 
group.  CDvsC is the control group, CDvsD is testosterone depletion during differentiation, 
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PPDvsP is testosterone depletion during proliferation, and PPDvsPD is testosterone depletion 
during the entire time course. 
 
Figure 11 displays the number of uniquely, differentially expressed proteins for the 3 treatment 
groups.  The proteins that were differentially expressed from the 0h to 96 hour of each grouping, 
and exclusive to said groupings (corresponding to 9 for C/D vs. C, 63 for C/D vs. D, 25 for P/PD 
vs. P, and 30 for P/PD vs. PD) were:  
Differentially Expressed Proteins Exclusive to the C/D vs. C Grouping 
Protein ID Protein Gene 
UBC_MOUSE Polyubiquitin-C Ubc  
SYNC_MOUSE Asparagine--tRNA ligase; cytoplasmic Nars 
RL14_MOUSE 60S ribosomal protein L14 Rpl14 
EIF3A_MOUSE Eukaryotic translation initiation factor 3 subunit A Eif3a  
E41L2_MOUSE Band 4.1-like protein Epb41l2  
PSME2_MOUSE Proteasome activator complex subunit 2 Psme2  
RCC1_MOUSE Regulator of chromosome condensation Rcc1 
GSTM7_MOUSE Glutathione S-transferase Mu 7 Gstm7  
GSTM2_MOUSE Glutathione S-transferase Mu 2 Gstm2  
 
Differentially Expressed Proteins Exclusive to the C/D vs. D Grouping 
Protein ID Protein Gene 
TBB3_MOUSE Tubulin beta-3 chain Tubb3  
ANXA2_MOUSE Annexin A2 Anxa2  
ANXA1_MOUSE Annexin A1 Anxa1  
MYH1_MOUSE Myosin-1 Myh1  
ENOB_MOUSE Beta-enolase Eno3  
MYH7_MOUSE Myosin-7 Myh7  
1433B_MOUSE 14-3-3 protein beta/alpha Ywhab 
TCPB_MOUSE T-complex protein 1 subunit beta Cct2  
TCPE_MOUSE T-complex protein 1 subunit epsilon Cct5 
MACF1_MOUSE Microtubule-actin cross-linking factor 1 Macf1  
MYO1C_MOUSE Unconventional myosin-Ic Myo1c  
TCPZ_MOUSE T-complex protein 1 subunit zeta Cct6a  
BASP1_MOUSE Brain acid soluble protein 1 Basp1 
PUR9_MOUSE Bifunctional purine biosynthesis protein PURH Atic 
RS3A_MOUSE 40S ribosomal protein S3a Rps3a 
HSP74_MOUSE Heat shock 70 kDa protein 4 Hspa4 
PRDX6_MOUSE Peroxiredoxin-6 Prdx6  
RS10_MOUSE 40S ribosomal protein S10 Rps10 
TRI72_MOUSE Tripartite motif-containing protein 72 Trim72 
RS3_MOUSE 40S ribosomal protein S3 Rps3  
RL3_MOUSE 60S ribosomal protein L3 Rpl3 
33 
 
CALX_MOUSE Calnexin Canx  
AATM_MOUSE Aspartate aminotransferase; mitochondrial Got2 
RINI_MOUSE Ribonuclease inhibitor Rnh1 
U5S1_MOUSE 116 kDa U5 small nuclear ribonucleoprotein component Eftud2  
PTRF_MOUSE Polymerase I and transcript release factor Ptrf  
PRDX2_MOUSE Peroxiredoxin-2 Prdx2  
SYK_MOUSE Lysine--tRNA ligase Kars 
MPCP_MOUSE Phosphate carrier protein; mitochondrial Slc25a3  
TKT_MOUSE Transketolase Tkt  
EIF3B_MOUSE Eukaryotic translation initiation factor 3 subunit B Eif3b  
IPO7_MOUSE Importin-7 Ipo7  
LRRF1_MOUSE Leucine-rich repeat flightless-interacting protein 1 Lrrfip1 
EIF3C_MOUSE Eukaryotic translation initiation factor 3 subunit C Eif3c  
SUGT1_MOUSE Suppressor of G2 allele of SKP1 homolog Sugt1  
ESYT1_MOUSE Extended synaptotagmin-1 Esyt1  
IF4B_MOUSE Eukaryotic translation initiation factor 4B Eif4b  
HNRPC_MOUSE Heterogeneous nuclear ribonucleoproteins C1/C2 Hnrnpc  
TAGL3_MOUSE Transgelin-3 Tagln3  
MARE1_MOUSE Microtubule-associated protein RP/EB family member 1 Mapre1  
EHD1_MOUSE EH domain-containing protein 1 Ehd1 
ODPA_MOUSE Pyruvate dehydrogenase E1 component subunit alpha; 
somatic form; mitochondrial 
Pdha1 
RAB10_MOUSE Ras-related protein Rab-10 Rab10  
ACADL_MOUSE Long-chain specific acyl-CoA dehydrogenase; mitochondrial Acadl 
UAP1L_MOUSE UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 Uap1l1  
RL21_MOUSE 60S ribosomal protein L21 Rpl21 
CATZ_MOUSE Cathepsin Z Ctsz  
ASNS_MOUSE Asparagine synthetase [glutamine-hydrolyzing] Asns 
TSP1_MOUSE Thrombospondin-1 Thbs1 
CN166_MOUSE UPF0568 protein C14orf166 homolog N/A 
MVP_MOUSE Major vault protein Mvp  
PSME3_MOUSE Proteasome activator complex subunit 3 Psme3 
EPHA2_MOUSE Ephrin type-A receptor 2 Epha2  
LIMA1_MOUSE LIM domain and actin-binding protein 1 Lima1  
HS105_MOUSE Heat shock protein 105 kDa Hsph1  
SNX1_MOUSE Sorting nexin-1 Snx1  
PTGR1_MOUSE Prostaglandin reductase 1 Ptgr1  
SPR1A_MOUSE Cornifin-A Sprr1a 
ABCF2_MOUSE ATP-binding cassette sub-family F member 2 Abcf2 
XRCC6_MOUSE X-ray repair cross-complementing protein 6 Xrcc6  
RB11B_MOUSE Ras-related protein Rab-11B Rab11b 
PP1R7_MOUSE Protein phosphatase 1 regulatory subunit 7 Ppp1r7 
MY18A_MOUSE Unconventional myosin-XVIIIa Myo18a 
 
 
 
34 
 
Differentially Expressed Proteins Exclusive to the P/PD vs. P Grouping 
Protein ID Protein Gene 
ACTN3_MOUSE Alpha-actinin-3 Actn3 
RTN4_MOUSE Reticulon-4 Rtn4  
DDX3Y_MOUSE ATP-dependent RNA helicase DDX3Y Ddx3y 
MYBPH_MOUSE Myosin-binding protein H Mybph  
SRCA_MOUSE Sarcalumenin Srl  
SAHH_MOUSE Adenosylhomocysteinase Ahcy  
PACN2_MOUSE Protein kinase C and casein kinase substrate in neurons 
protein 2 
Pacsin2  
ETFB_MOUSE Electron transfer flavoprotein subunit beta Etfb 
FAS_MOUSE Fatty acid synthase Fasn  
TXND5_MOUSE Thioredoxin domain-containing protein 5 Txndc5  
ATP5H_MOUSE ATP synthase subunit d; mitochondrial Atp5h  
USO1_MOUSE General vesicular transport factor p115 Uso1  
RS11_MOUSE 40S ribosomal protein S11 Rps11  
SYP2L_MOUSE Synaptopodin 2-like protein Synpo2l  
TNNI1_MOUSE Troponin I; slow skeletal muscle Tnni1  
GPDM_MOUSE Glycerol-3-phosphate dehydrogenase; mitochondrial Gpd2  
GATM_MOUSE Glycine amidinotransferase; mitochondrial Gatm 
CO1A2_MOUSE Collagen alpha-2(I) chain Col1a2 
TNNT2_MOUSE Troponin T; cardiac muscle Tnnt2  
TMM43_MOUSE Transmembrane protein 43 Tmem43  
MCM6_MOUSE DNA replication licensing factor MCM6 Mcm6  
CDK4_MOUSE Cyclin-dependent kinase 4 Cdk4  
THIM_MOUSE 3-ketoacyl-CoA thiolase; mitochondrial Acaa2  
TNNT3_MOUSE Troponin T; fast skeletal muscle Tnnt3  
CDK13_MOUSE Cyclin-dependent kinase 13 Cdk13  
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Differentially Expressed Proteins Exclusive to the PD/P vs. PD Grouping 
Protein ID Protein Gene 
HS90B_MOUSE Heat shock protein HSP 90-beta Hsp90ab1  
TAGL_MOUSE Transgelin Tagln  
NPM_MOUSE Nucleophosmin Npm1  
LRC59_MOUSE Leucine-rich repeat-containing protein 59 Lrrc59  
STIP1_MOUSE Stress-induced-phosphoprotein 1 Stip1  
LMNB1_MOUSE Lamin-B1 Lmnb1  
ANXA4_MOUSE Annexin A4 Anxa4  
RS13_MOUSE 40S ribosomal protein S13 Rps13  
RL7A_MOUSE 60S ribosomal protein L7a Rpl7a  
SPTB2_MOUSE Spectrin beta chain; non-erythrocytic 1 Sptbn1 
TYB4_MOUSE Thymosin beta-4 Tmsb4x  
IF4G1_MOUSE Eukaryotic translation initiation factor 4 gamma 1 Eif4g1 
THIO_MOUSE Thioredoxin Txn  
C1TC_MOUSE C-1-tetrahydrofolate synthase; cytoplasmic Mthfd1 
RAGP1_MOUSE Ran GTPase-activating protein 1 Rangap1 
CALU_MOUSE Calumenin Calu 
PPIC_MOUSE Peptidyl-prolyl cis-trans isomerase C Ppic  
NOP2_MOUSE Putative ribosomal RNA methyltransferase NOP2 Nop2  
VAT1_MOUSE Synaptic vesicle membrane protein VAT-1 homolog Vat1  
GNAI2_MOUSE Guanine nucleotide-binding protein G(i) subunit alpha-2 Gnai2 
NDRG1_MOUSE Protein NDRG1 Ndrg1  
ODPB_MOUSE Pyruvate dehydrogenase E1 component subunit beta; 
mitochondrial 
Pdhb  
SC23A_MOUSE Protein transport protein Sec23A Sec23a  
KAD2_MOUSE Adenylate kinase 2; mitochondrial Ak2  
RL9_MOUSE 60S ribosomal protein L9 Rpl9 
NCAM1_MOUSE Neural cell adhesion molecule 1 Ncam1 
CTNB1_MOUSE Catenin beta-1 Ctnnb1 
SAFB1_MOUSE Scaffold attachment factor B1 Safb  
VMA5A_MOUSE von Willebrand factor A domain-containing protein 5A Vwa5a 
SC22B_MOUSE Vesicle-trafficking protein SEC22b Sec22b 
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E. Discussion 
Upstream Regulators of differentiation - The determination of key pathway changes during the 
differentiation program was of utmost importance, so that the testosterone depletion study had a 
baseline to compare.  Serum response factor (SRF), insulin signaling, and p53 were identified 
as regulators of the differentiation process in our IPA analysis.  SRF has been shown to 
modulate differentiation through activation-motivated binding of myogenin and MyoD[18].  SRF 
also has the ability to bind to the AR and facilitate myogenesis through activation of myogenic 
genes within the nucleus[19].   
 
p53 is a crucial trigger to muscle cell differentiation[20], and acts through the retinoblastoma 
protein (pRb).  In order for myoblasts to differentiate, they must exit the cell cycle.  p53 activates 
pRb which causes cell cycle withdrawal, and induction into the differentiation program[21].  
Continued expression of pRb keeps the differentiating myoblasts from re-entering the cell cycle, 
thus p53 is critical to the activation of the differentiation program.   
 
The insulin-like growth factor 1 receptor (IGF-IR) has been shown to play a role in the 
proliferation and differentiation of myoblasts[22] through binding of insulin-like growth factor-II 
(IGF-II).  IGF-1 also plays a crucial role during the cell cycle through positive regulation of the 
mTOR signaling pathway[23, 24].  To further the discussion, insulin-like growth factor binding 
proteins (IGFBP) have the ability to bind to IGF molecules, and inhibit the binding of IGF to the 
receptor[25].  IGFBP5 specifically binds to IGF-II to restrict signaling to the IGF receptors, which 
stalls proliferation and differentiation of myoblasts[25].  On the contrary, IGFBP5 binds IGF-I to 
stimulate myogenesis[25].  The roles of IGFBP5, IGF-I, and IGF-II are important to the 
understanding of the proliferation and differentiation processes within skeletal muscles, and 
seem to provide pathways by which the differentiation program can be activated.   
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Through the identification of the key regulators during the differentiation program, we are better 
able to study the exact mechanisms of T depletion on myogenesis. 
 
Implications of testosterone depletion during differentiation – 
Pax7 and Myogenin: 
An important part of the differentiation process is the change from a Pax7 expressing 
myoblast[6] into a myogenin expressing myocyte and eventually a myotube.  Muscle cells must 
undergo this Pax7 maturation process in order to become fully differentiated myotubes[11].  
Pax7 expression is not detectable in fully differentiated myotubes[11, 26], and is down-regulated 
in order for differentiation to occur.  The Pax7 proliferation process is critical to the development 
of myotubes, and the down-regulation coupled with the de-expression of Pax7 protein allows for 
terminal differentiation to occur[26].  Within our cultures, both the D and PD treatment groups – 
which both were depleted of T during the differentiation process – presented with up-regulated 
Pax7 expression at the 96h time point coupled with down-regulated myogenin. The trend of 
Pax7 up-regulation and myogenin down-regulation at the peak of differentiation suggests that 
when the culture was depleted of T during the differentiation period, the cells were unable to 
fuse in order to form multinucleated myotubes, and were essentially in a state of continued 
proliferation.   
 
Insulin-Like Growth Factor Signaling: 
IGF signaling plays a role in both the proliferation and differentiation of myoblasts as previously 
stated.  The increased expression of IGF-1 in 96h time point of testosterone depletion alongside 
the Pax7 up-regulation and myogenin down-regulation further suggests that a proliferative state 
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is ongoing.  IGF-1 acts as a mitogen in the mTOR signaling pathway[23], and thus the 
increased expression could point towards a continued activation of this pathway, and a 
continued proliferative state.  Further research into the interactions of IGF-I and testosterone 
must be used to clarify the impact of IGF-I on endocrine signaling, along with its specific role in 
the muscle differentiation and proliferation processes. 
 
Acta1 (alpha actin 1), Myh1 (myosin heavy chain 1), and Myh2 (myosin heavy chain 2): 
A combination of actin and myosin filaments in skeletal muscle allow for muscle 
contractions[27].  The combined action of myosin sliding past actin filaments contracts the 
muscles, and generates force.  Acta1 mutations in humans are associated with myopathy and 
muscle weakness[28].  Mutations to the Acta1 gene are characteristic to nemaline myopathy, 
which leads to weakness of the arms, legs, and trunk muscles.  Alpha-actin 1 was shown to be 
down-regulated at the 96h time point when T was depleted during differentiation, which 
suggests the muscles possess a reduced ability to contract.  Acta1 when under-expressed 
could lead to myopathy type states, but further research must be employed to verify. 
 
Heat Shock Protein and AR Signaling:  
Heat shock protein 90 (HSP90) is bound to AR without ligand while in the cytoplasm, and 
increases the AR’s affinity to binding of hormones[29].  While bound to HSP90 the AR cannot 
bind to DNA [29], and must dissociate first through androgen binding.  Once androgens bind, 
HSP90 assists in transforming the AR into a DNA-binding state[30, 31], and HSP90 also helps 
transfer the AR to the nucleus so that the AR can activate target genes[32].  The highest count 
protein that was differentially expressed proteomically at the 96h of the PD group was HSP90.  
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The high-count state of HSP90 could point towards a stalled growth process of the myoblasts, 
because there are no androgens available to bind to the AR, and cause translocation to the 
nucleus for differentiation activation.  Further investigation into this mechanism is necessary to 
confirm our ideas. 
 
 
F. Conclusions 
The study presented here provided a vast array of data that provides a thorough basis for 
further studies to be designed.  The regulators of differentiation have been identified and 
qualitatively correlated with their proposed function in regards to testosterone depletion, and a 
possible biomarker for testosterone status has been identified in HSP90.  The basis set of data, 
which is comprised of proteomic, transcriptional, and pathway analyses, provides a multitude of 
future directions, and the molecular mechanisms of testosterone depletion are being unraveled, 
and will continue to be determined in the near future. 
 
 
G. Future Directions 
Due to the exploratory nature of our investigation, the amount of data collected provides for 
multiple further analyses.  The first direction is identifying the AR within the nucleus versus the 
AR in the cytoplasm of the differentiation phase testosterone-depleted cells at 96h.  HSP90 wil 
be measured to find the correlation between the AR bound HSP90 and unbound nucleus-
localized AR. 
 
The next possible investigation is into the specific link between T and insulin signaling 
pathways, determining the common link that connects these two pathways.  We propose that 
the AR is the common link, but this must be studied further. 
40 
 
 
Metabolomics of the cells under the depletion conditions is of utmost interest.  IPA identified key 
metabolic pathways changing during the differentiation program, namely glycolysis, beta-
oxidation, and the TCA cycle.  Metabolomics could provide a biomarker for testosterone status 
that could be translated to drug testing, as well as muscle function in patients. 
 
Lastly, pharmacological ADT agents will be tested in culture to determine if they have their own 
specific mechanisms of action on myoblasts, separate from testosterone depletion solely.  
Essentially ADT drugs inhibit the production or signaling of androgens, such as testosterone, 
through the androgen receptor (AR), which in turn inhibits the proliferation of testosterone 
sensitive tissues, including prostate cancer and muscle.  A diagram of the androgen signaling 
process is pictured above (pg. 2), including the specific mechanisms of action of clinically 
relevant ADT agents. However the specific impact of the AR targeting agents on skeletal muscle 
has not been well studied. 
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